The company partnered with AstraZeneca and BioMarin to identify which cancer patients respond to experimental cancer drugs.
Amgen raises price of Enbrel by 10%; pharma companies appear to raise diabetes drug prices in tandem; Alexion agrees to buy rare-disease drugmaker for $8.4 billion
A study found that cost-effectiveness and clinical-effectiveness measures often point to the same treatment protocol.
Hernandez is known for his ability to bring together patients and pharma. He joined Livongo Health to aid the firm's user experience.
Worldwide spending on cancer medications hit $100 billion last year; Bayer adds an anticoagulant to its pipeline for $100 million; GlaxoSmithKline has a new chairman
The IMS Institute for Healthcare Informatics says makers of cancer drugs will need more than data points for payers to see the value in their pricey new treatments.
A Pfizer poll shows patients rely on over-the-counter medications but need help finding the right treatment.
With 13 categories added in the last two years, there are more ways to win than ever. What could be better? We just extended the entry deadline by a week.
Drugmakers engage early with insurers; patients push for implant to be pulled from the market; about one-third of new drugs qualify for special approval pathways
Four start-ups presented their business models to pharma executives during the MM&M Transforming Healthcare conference on Thursday in New York City.
Nexium tops the list of Medicare's spending on brand drugs; Gilead Sciences doubles its first-quarter profit; Pfizer reportedly wants to buy a rare-disease drug company
The 2015 healthcare agency questionnaire, for firms hoping to be featured in the Top 100 Agencies issue, is live. Click here to be considered.